Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000419 · ClinicalTrials.gov registry record · Phase 3
Safety of Estrogens in Lupus: Hormone Replacement Therapy
A Phase 3 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00000419: Clinical Trial Phase 3 study, sponsored by NYU Langone Health.
NCT00000419 is a Phase 3 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 350 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000419, a Phase 3 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
Interventions
- DRUG Premarin and Provera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 1996-04 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Why NCT00000419 stopped before completion
NCT00000419 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which Premarin and Provera is the first listed.
NCT00000419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000419 about?
NCT00000419 is a clinical study titled "Safety of Estrogens in Lupus: Hormone Replacement Therapy". Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on t...
What is the current status of trial NCT00000419?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 1996-04. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00000419?
The interventions under investigation include: Premarin and Provera (DRUG).
Who is sponsoring clinical trial NCT00000419?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000419's enrollment target sits among peer trials
350 1034th of 2000 higher than 956 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia